Clinical Trial Applications: Filter, Search, and view applications
# | Protocol No | Study Title | Investigator(s) & Site(s) | |
---|---|---|---|---|
296. |
ECCT/23/06/02 | IMAGINE-TBM A Phase II, Randomized, Open-Label Trial of a Six-Month Regimen of High-Dose Rifampicin, High-Dose Isoniazid, Linezolid, and Pyrazinamide versus a Standard Nine-Month Regimen for the Treatment of Adults and Adolescents with Tuberculous Meningitis: Improved Management with Antimicrobial AGents Isoniazid rifampiciN LinEzolid for TBM (IMAGINE-TBM). |
Principal Investigator(s) 1. Deborah Chepng\'eno Langat Site(s) in Kenya KEMRI/WRP CRC |
View |
297. |
ECCT/23/05/02 | A5384 A Phase II, Randomized, Open-Label Trial of a Six-Month Regimen of High-Dose Rifampicin, High-Dose Isoniazid, Linezolid, and Pyrazinamide versus a Standard Nine-Month Regimen for the Treatment of Adults and Adolescents with Tuberculous Meningitis: Improved Management with Antimicrobial AGents Isoniazid rifampiciN LinEzolid for TBM (IMAGINE-TBM) |
Principal Investigator(s) 1. Abraham Siika Site(s) in Kenya 1. Moi University Clinical Research Centre (Uasin Gishu county) 2. KEMRI Walter Reed Project (Kericho county) |
View |
298. |
ECCT/13/08/01 | M72/AS01 E A phase IIb, double-blind, randomised, placebo-controlled study to evaluate the efficacy, safety and immunogenicity of GSK Biologicals’ candidatetuberculosis (TB) vaccine GSK 692342 against TB disease, in healthy adults aged 18-50 years, living in a TB endemic region. |
Principal Investigator(s) 1. Dr Videlis Nduba Site(s) in Kenya KEMRI-CDC |
View |
299. |
ECCT/23/02/06 | BOHEMIA Safety and Efficacy A Phase III cluster-randomized, open-label, clinical trial to study the safety and efficacy of ivermectin mass drug administration to reduce malaria transmission in Kwale, Kenya. |
Principal Investigator(s) 1. Marta Ferreira Maia 2. Joseph Mwangangi Site(s) in Kenya Kwale county, subcounties Lungalunga and Msambweni |
View |
300. |
ECCT/20/10/04 | yellow fever vaccine CVIA 079 A Phase III double-blind, randomized, active comparator controlled study in healthy Kenyan adolescents, young children and infants to assess the safety and immunogenicity of Beijing Institute of Biologic Products (BIBP) yellow fever vaccine in comparison to a WHO 17D-204 prequalified comparator yellow fever vaccine, as well as lot-to-lot consistency of immune response to the BIBP yellow fever vaccine”, CVIA 079. |
Principal Investigator(s) 1. Dr. Deborah Langat Site(s) in Kenya KEMRI/KERICHO CLINIC RESEARCH CENTRE |
View |